Chandra Bhagat Pharma Limited (BOM:542934)
India · Delayed Price · Currency is INR 41.80
-2.20 (-5.00%)
At close: Jun 23, 2026
Chandra Bhagat Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,163 | 867.16 | 2,214 | 1,197 | 940.76 |
Other Revenue | -0 | 20.51 | 11.3 | - | - |
| 1,163 | 887.67 | 2,225 | 1,197 | 940.76 | |
Revenue Growth (YoY) | 30.99% | -60.10% | 85.93% | 27.21% | 33.07% |
Cost of Revenue | 935.63 | 734.81 | 2,083 | 1,068 | 814.41 |
Gross Profit | 227.09 | 152.86 | 142.31 | 129.04 | 126.34 |
Selling, General & Admin | 30.08 | 29.36 | 29.68 | 18.25 | 21.31 |
Other Operating Expenses | 124.95 | 91.74 | 74.53 | 71.48 | 52.63 |
Operating Expenses | 166.01 | 130.62 | 110.63 | 92.39 | 75.18 |
Operating Income | 61.08 | 22.24 | 31.69 | 36.66 | 51.17 |
Interest Expense | -20.03 | -17.96 | -12.87 | -21.75 | -29.84 |
Interest & Investment Income | - | 0.16 | 0.07 | 0.03 | 1.54 |
Currency Exchange Gain (Loss) | - | 6.76 | 7.7 | -0.61 | -9.29 |
Other Non Operating Income (Expenses) | 0 | -1.52 | -1 | -0.23 | -2.53 |
EBT Excluding Unusual Items | 41.05 | 9.68 | 25.58 | 14.09 | 11.05 |
Gain (Loss) on Sale of Investments | - | - | - | 0.01 | - |
Gain (Loss) on Sale of Assets | - | 2.31 | - | - | - |
Pretax Income | 41.05 | 11.99 | 25.58 | 14.11 | 11.05 |
Income Tax Expense | 10.59 | 3.41 | 10.28 | 5.05 | 3.08 |
Net Income | 30.46 | 8.58 | 15.3 | 9.05 | 7.97 |
Net Income to Common | 30.46 | 8.58 | 15.3 | 9.05 | 7.97 |
Net Income Growth | 255.11% | -43.95% | 69.02% | 13.64% | 319.54% |
Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 |
Shares Change (YoY) | -0.07% | - | - | - | - |
EPS (Basic) | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 |
EPS (Diluted) | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 |
EPS Growth | 255.35% | -43.95% | 69.02% | 13.64% | 322.37% |
Free Cash Flow | 83.15 | -67.84 | 38.94 | 48.96 | 122.99 |
Free Cash Flow Per Share | 11.03 | -8.99 | 5.16 | 6.49 | 16.30 |
Gross Margin | 19.53% | 17.22% | 6.40% | 10.78% | 13.43% |
Operating Margin | 5.25% | 2.50% | 1.42% | 3.06% | 5.44% |
Profit Margin | 2.62% | 0.97% | 0.69% | 0.76% | 0.85% |
Free Cash Flow Margin | 7.15% | -7.64% | 1.75% | 4.09% | 13.07% |
EBITDA | 71.37 | 31.06 | 36.56 | 37.77 | 51.55 |
EBITDA Margin | 6.14% | 3.50% | 1.64% | 3.16% | 5.48% |
D&A For EBITDA | 10.3 | 8.82 | 4.87 | 1.11 | 0.38 |
EBIT | 61.08 | 22.24 | 31.69 | 36.66 | 51.17 |
EBIT Margin | 5.25% | 2.50% | 1.42% | 3.06% | 5.44% |
Effective Tax Rate | 25.80% | 28.45% | 40.18% | 35.82% | 27.89% |
Revenue as Reported | 1,196 | 922.05 | 2,327 | 1,200 | 956.96 |
Advertising Expenses | - | 0.02 | 1.03 | - | 0.38 |